Other substances

Bemcentinib

A tyrosine kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Bemcentinib is an AXL receptor tyrosine kinase selective inhibitor. It has been investigated for its antineoplastic activity (NCIt).

Bemcentinib on DrugBank
Bemcentinib on PubChem
Bemcentinib on Wikipedia

Synonyms

R428; BGB324

C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs 3CLpro Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Nov/05/2020
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 Small molecule In vitro Screening	Huh7.5 cells; Calu-3 cells; primary normal human bronchial epithelial cells; iPSC-derived AT2 cells; SARS-CoV-2 strain USA WA1/2020	8.11	Inhibited SARS-CoV-2 replication in Huh7.5 cells and also in Calu-3 cells with an SI of >3.	Mar/23/2021

AI-suggested references

Link	Publication date
Bemcentinib and gilteritinib inhibit cell growth and impair the endo-lysosomal and autophagy systems in an AXL-independent manner.	Dec/15/2020
Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study	Jul/08/2021
Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies.	Sep/20/2021
Phosphatidylserine receptors enhance SARS-CoV-2 infection	Feb/28/2022
Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA	May/10/2020
Virtual high throughput screening: Potential Inhibitors for SARS-CoV-2 PLPRO and 3CLPRO Proteases	May/05/2021
In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease	Nov/11/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04890509	A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients	Completed	Phase 2	Oct/20/2020	May/25/2021
Alternative id - BGBC020 Interventions - Drug: Bemcentinib\|Other: SoC Study type - Interventional Study results - No Results Available Locations - Nirmal Hospital Private Limited, Surat, Gujarat, India\|Kasturba Medical College, Mangalore, Karnataka, India\|JSS Hospital, Mysuru, Karnataka, India\|Chopda Medicare & Research Centre Pvt. Ltd (CMARC) - Magnum Heart Institute, Nashik, Maharashtra, India\|Sahyadri Specialty Hospital, Pune, Maharastra, India\|Krishna Institute of Medical Sciences (KIMS Hospitals), Secunderabad, Telangana, India\|Maulana Azad Medical College, New Delhi, India\|Worthwhile Clinical Trials, Lakeview Hospital, Mowbray, Benoni, South Africa\|Tiervlei Trial Centre, Bellville, Cape Town, South Africa\|Vergelegen Mediclinic, Somerset West, Cape Town, South Africa\|Into Research, Groenkloof, Pretoria, South Africa\|Clinical Projects Research, Worcester, South Africa Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 115 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Sustained Clinical Improvement of at Least 2 Points (from randomization)\|Percentage of Participants not Deteriorating According to the Ordinal Scale by 1, 2, or 3 Points\|Duration of Oxygen Use\|Number of Oxygen-free Days\|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load\|Duration of Ventilation\|Number of Ventilation-free Days\|Number of Participants with Any Form of New Ventilation Use\|Duration of New Ventilation Use\|Duration of Organ Support\|Number of Participants with Response\|Time to Live Discharge From the Hospital\|Time From Treatment Start Date to Death\|Overall Mortality\|Change in the Ratio of Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2)\|Number of Participants with Physical Examination Abnormalities\|Number of Participants with Clinical Laboratory Abnormalities\|Number of Participants with Vital Signs (blood pressure/heart rate/temperature/respiratory rate) Abnormalities\|Number of Participants with Adverse Events (AEs)\|Duration of Intensive Care Unit (ICU) and Hospitalization\|National Early Warning Score 2 (NEWS2)\|Time to NEWS2 of <=2, Maintained for at Least 24 Hours\|Ranked Trajectory

Export (.csv)